Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease

touchEXPERT FOCUS for touchONCOLOGY Listen to a series of short interviews with three leading experts discussing the application of immunotherapy in triple-negative breast cancer (TNBC). The experts explore the latest data and guideline recommendations for immunotherapy in early-stage and metastatic TNBC, and how to maximize treatment benefits.  The experts: Prof. Sherko Kümmel – Kliniken Essen-Mitte, Essen, Germany Prof. Rebecca Dent – National Cancer Center Singapore, Singapore Prof. Peter Schmid – Barts Cancer Institute, London, UK This touchPODCAST is for healthcare professionals outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.  This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/management-of-tnbc-with-immunotherapy/